The incidence of Merkel cell carcinoma, an aggressive neuroendocrine skin cancer, has grown rapidly since the disease was first described in 1972.
The NCCN has released new clinical practice guidelines for the management of cancer in people living with HIV.
The FDA has granted Breakthrough Therapy and Fast Track designation to GC4419, for reduction of severe oral mucositis caused by radiation therapy.
The oral therapy combination of ixazomib, pomalidomide, and dexamethasone was effective and well-tolerated in patients with myeloma that had relapsed or was refractory to lenalidomide.
In this UK observational study, being obese was linked with an increased risk for colorectal cancer but undergoing prior obesity surgery was not.
In a large Chinese study, in certain RCC subgroups cancer-specific survival outcomes were better with partial rather than radical nephrectomy.
Patients who received Bacteroides-targeting antibiotics had a median PFS of 18 months compared with 8 months in patients with no antibiotic use.
Nearly 80% of R/R myeloma patients with severe renal impairment requiring hemodialysis achieved disease control with this treatment combination.
DLBCL patients who received in-hospital chemotherapy had a lower risk of death during hospitalization.
CLL patients responded well to induction with the RCC regimen cladribine, cyclophosphamide, and rituximab followed by maintenance rituximab.